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ABSTRACT: The feasibility of the Depressurization of an Expanded Liquid Organic Solution
(DELOS) method to process different active pharmaceutical ingredients (APIs) as finely divided
powders with narrow particle size distribution, high crystallinity degree, high polymorphic purity,
and free from residual solvent has been demonstrated. Cholesterol, acetylsalicylic acid (aspirin),
naproxen, acetaminophen, and ibuprofen were chosen as model drugs. It has been demonstrated
that the supersaturation ratio attained during crystallization from CO2-expanded solvents can be
modulated through appropriate variations of process parameters  CO2 content and
concentration of the initial solution. In view of the potential application that compressed fluids-
based technologies have in the pharmaceutical industry, a preliminary scalability study of the
process in compliance with the constraints imposed by the Good Manufacturing Practices (GMP)
specifications is presented herein.
1. INTRODUCTION
The 21st century challenge in the pharmaceutical industry does
not exclusively focus on the development of new therapeutic
molecules but is also concerned with the search for better
delivery routes and combined formulations to increase
bioavailability of already developed drugs. Development of
new drugs is expensive, risky, and slow, taking up to 15 years to
obtain full accreditation, so pharmaceutical companies are keen
to investigate new formulations that can deliver or target
existing drugs more effectively. Among others, one strategy
consists of the preparation of active ingredients as micro- and
nanoparticulate solids, since the therapeutic activity of
pharmaceutical entities is related to the chemical structure
but also to physical factors such as crystallinity, polymorphism,
and particle size. Effective administration of the majority of new
developed pharmaceutical drugs is related to the control over
their pharmacokinetic properties through physical modifica-
tion.1 Fine particles with a narrow particle size distribution,
which have a high surface area, generally increase the
bioavailability and dissolution rate of pharmaceuticals.2 For
example, drugs administered orally are limited by its dissolution
rate in the gastrointestinal tract. In addition, prescribed doses
can be reduced by improving the drug dissolution rate in the
biological environment.3 Therapeutic compounds in the form
of micropowders offer convenient and controllable delivery by
subcutaneous, intramuscular, topical, and intestinal modes.
Controlled particle characteristics also create opportunities for
alternative delivery systems to be explored, such as powder
injection (a needle-free technique for the transdermal delivery
of micronized drugs).4 Particle size is one of the critical factors
for the determination of appropriate administration routes. The
ideal micrometer-sized pharmaceutical should retain the
original crystallinity, polymorphism, and chemical activity of
the raw material and should be in the form of free-flowing,
nonaggregated, monodispersed, and polymorphically pure
powder.
Standard procedures for generating particulate solids are
usually multistep processes consisting of a precipitation/
crystallization followed by additional downstream steps for
particle size reduction and homogenization. Even though these
methodologies are still the most used, they are not always
adequately responsive to market and clinical demands because
of undesired product transformations (i.e., polymorphic
transitions), inapplicability to thermolabile or waxy materials,
low batch-to-batch reproducibility, and complex scale-up.
Besides, crystallization/precipitation from liquid solvents is
limited by the low control over particle size distribution and
also by the difficulty of complying with residual solvent
acceptable limits imposed by regulatory agencies, for example,
ICH Guidelines or pharmacopoeias.5 Many industrial solvents
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are not only hazardous (toxic, flammable, etc.), but their full
recovery and recycling are often not easy.
In recent years, several particle formation techniques based
upon the utilization of compressed fluids (CF) as crystallization
media have been developed.6−8 Most of these technologies
have in common the use of CO2 as CF since it is nontoxic,
nonflammable, cheap, and easily recyclable. Among these, in
the past decade we have reported the Depressurization of an
Expanded Liquid Organic Solution (DELOS) process, which
involves the use of a CF for the one-step production of
micrometer-sized and sub-micrometer-sized crystalline particles
of high polymorphic purity and morphological homogene-
ity.9−11 The driving force of this crystallization process is the
fast, large, and extremely homogeneous temperature decrease
experienced by a solution of the compound to crystallize in an
organic solvent expanded with a CF, when it is depressurized
from a given working pressure to atmospheric pressure. This
method presents a new and interesting route for pharmaceutical
particle formation which avoids most drawbacks of traditional
methods. The methodology is shown in Figure 1 and has been
extensively described elsewhere.9−11
The first step of this process consists of the dissolution of the
drug in a conventional organic solvent, at atmospheric pressure
and working temperature (TW), to form a solution with an
initial concentration CI. Second, the initial solution is
pressurized up to the working pressure (PW) by the addition
of a given amount of CO2, expressed by the CO2 molar fraction
of the mixture “organic solvent/CO2” (XW). In this second step,
the solute concentration (CW) should remain below the
saturation limit in the CO2-expanded mixture, that is, the
solute is soluble in the CO2-expanded mixture showing a single
liquid phase. In the third step, the solution is depressurized
from the working pressure PW to atmospheric pressure, through
a nonreturn simple valve. During this depressurization step, the
CO2 evaporates very rapidly from the solution producing a
large, fast, and extremely homogeneous decrease of the solution
temperature down to a final temperature, TF. Differently from
conventional cooling crystallization processes, it can be
assumed that in this case, TF is reached before primary
nucleation takes place and therefore, as schematized in Figure
1, the initial solute concentration is re-established (CF = CI)
during this third step. The consequence of this abrupt
temperature decrease ΔT (ΔT = TF − TW) is a fast,
pronounced, and very homogeneous increase of the super-
saturation all over the solution  CF becomes higher than the
solute solubility in the conventional solvent at the final
temperature, CF
S  causing the precipitation of finely divided
crystalline powders with narrow particle size distribution.
Under the conditions of the DELOS crystallization, it could be
considered that the difference between CI and CF
S, ΔC (ΔC =
CI − CFS) is the maximum supersaturation achieved and the
supersaturation ratio can be calculated as S = CI /CF
S. Thus, the
higher ΔC, the higher the maximum supersaturation attained,
and more favored will be nucleation over crystal growth,
provoking the crystallization of small particles.12
In the present work, we demonstrate the feasibility of
producing micrometer-sized particles using this process, with
narrow particle size distribution and high polymorphic purity,
of five different pharmaceutical active ingredients. In the first
part, the relationship between process parameters carbon
dioxide content XW and initial concentration CI, with the
crystallization conditions achieved during the depressurization
of the CO2-expanded solution (final temperature TF and
solubility at final temperature CF
S), is described. In the second
part, the crystallization outcome (yield and particle size) is
discussed in relation to the supersaturation ratio S attained in
the third step due to the abrupt and homogeneous temperature
decrease. The specific weight of process parameters CI and XW
on the supersaturation ratio and therefore on particle
characteristics has been studied, and a procedure to predict
the parameter importance, related to drug solubility behavior, is
presented. Aspirin (ASP) and acetaminophen (ACPH), as
analgesic and antipyretic compounds, ibuprofen (IBU) and
naproxen (NAP), as nonsteroidal anti-inflammatory agents, and
Figure 1. Top: DELOS steps. Bottom: Example of the evolution of the solute concentration at each of the three steps of the process (red points) in
relation to the solubility curve of the solute in the CO2-expanded solvent (black solid line), at a working pressure PW and working temperature TW.
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cholesterol (COL), as a steroid model compound, are the drugs
chosen to carry out this study (Scheme 1). These drugs show
distinct lipophilicity degrees and large differences in water
solubility, being therefore representative of different types of
pharmaceutical active compounds. Particle size distribution,
morphology, crystallinity, and crystalline nature of the powders
obtained have been characterized. In relation to the industrial
viability of the process, a desirable manufacturing method for
the processing of APIs should be easily scalable, economically
viable, and easily compliant with the restrictions of Good
Manufacturing Practices (GMPs). Because of this, the process
studied has emerged as a promising green, scalable, and
industrially viable methodology, as the results of a very recent
study show,13 which are summarized in the final section.
2. MATERIALS AND METHODS
2.1. Materials and Solvents. Aspirin (99.5%), acetaminophen
(99%), cholesterol (99%), ibuprofen (99%), and naproxen (98%) were
purchased from SIGMA-Aldrich (Steinheim, Germany). Concerning
solvents, acetone (99.5%) was bought from QUIMIVITA (Barcelona,
Spain), and ethanol (99.5%) from PANREAC (Barcelona, Spain).
CO2 (purity 99.995%) was supplied by Carburos Metaĺicos S.A.
(Barcelona, Spain). All chemicals were employed without further
purification.
2.2. Experimental Details of Crystallizations. Crystallization
experiments were performed according to the usual three steps
represented in Figure 1. Acetone or ethanol was employed as
conventional organic solvents. Experimental apparatus and procedures
used to perform crystallization experiments are described in detail in
previous works.9−11 A known volume of a solution of the API in an
organic solvent, of known initial concentration CI was loaded in a lab-
scale high-pressure vessel (300 mL). During all experiments the
working temperature TW was kept constant. The initial solution was
then pressurized up to the desired working pressure PW by addition of
a given amount of CO2, XW. After leaving the system under the same
conditions for 30−60 min to achieve complete homogenization and
thermal equilibration, the solution was depressurized over a nonreturn
valve from PW to atmospheric pressure. When the solution
depressurization started, the temperature, registered after the
depressurization valve, decreased suddenly until reaching a constant
value. This final temperature value was taken as TF and the
temperature decrease was calculated as follows: ΔT = TF − TW. The
precipitated particles were recovered on a filter (pore size 200 nm).
After filtration the recovered particles were dried with a CO2 flow at
40 bar for 30 min.
2.3. Drug Particle Characterizations. Particle size distributions
were measured with a laser diffraction particle size analyzer (Beckman
Coulter model LS13320). Water with 0.1% (v/v) of polyoxyethylene
(20) sorbitan monooleate (Tween 80) was employed as a dispersing
medium in cholesterol, naproxen, and ibuprofen measurements,
whereas a high-boiling point petroleum fraction was used in aspirin
and acetaminophen particle size determinations. Particles morphology
was observed using a HITACHI model S-570 scanning electron
microscope (SEM). Powder X-ray diffraction analyses were performed
using a RIGAKU DS5000 diffractometer to ascertain if changes in
crystallinity and polymorphism occurred after drug processing. For
each sample, powder X-ray diffraction patterns were collected during 1
h between 2θ angles of 3 and 40. Thermogravimetric analyses (TGA)
were performed to evaluate residual solvent amounts in the processed
samples. These analysis were recorded with a STA 449-F1 Jupiter
(NETZSCH), using the NETZSCH Proteus software. Samples of
Scheme 1. Molecular Formula of Selected Drugsa
a(a) Aspirin (ASP), (b) acetaminophen (ACPH), (c) ibuprofen
(IBU), (d) naproxen (NAP), and (e) cholesterol (COL).
Table 1. Operating Conditions, Cooling, and Supersaturation Ratios Achieved in Crystallization Experiments of the Selected
Model Drugs from CO2-Expanded Solvents
expa solvent PW (MPa) TW (K) CI
b (mol/mol) XW
c TF
d (K) ΔTe (K) CFSf (mol/mol) ΔCg (mol/mol) Sh
ASP1 acetone 7 295 7.0 × 10−2 0.40 268 −27 5.6 × 10−2 0.014 1.3
ASP2 acetone 7 295 7.0 × 10−2 0.47 262 −33 4.8 × 10−2 0.022 1.5
ASP3 acetone 7 295 5.2 × 10−2 0.55 247 −48 2.8 × 10−2 0.024 1.9
ASP4 acetone 7 295 3.5 × 10−2 0.55 247 −48 2.8 × 10−2 0.007 1.3
ASP5 ethanol 7 298 8.1 × 10−2 0.55 234 −64 4.8 × 10−3 0.076 17
COL1 acetone 10 308 5.1 × 10−3 0.50 258 −50 6 × 10−4 0.0045 9
COL2 acetone 10 308 5.1 × 10−3 0.64 248 −60 3 × 10−4 0.0048 17
COL3 acetone 10 308 3.8 × 10−3 0.71 238 −70 3 × 10−4 0.0035 13
COL4 acetone 10 308 2.6 × 10−3 0.71 233 −75 3 × 10−4 0.0023 9
NAP1 ethanol 10 298 8.8 × 10−3 0.80 208 −90 2.3 × 10−3 0.007 4
IBU1 acetone 10 298 1.7 × 10−1 0.80 223 −75 1.8 × 10−2 0.152 9
ACPH1 ethanol 10 315 6.6 × 10−2 0.40 275 −40 3.4 × 10−2 0.032 2
aASP means aspirin; COL means cholesterol; NAP means naproxen; IBU means ibuprofen; ACPH means acetaminophen. bCI is the concentration
of solute in the initial organic solution. cCO2 content, XW = CO2 molar fraction in the solvent mixture.
dTemperature achieved at the
depressurization step, when the crystallization takes place. eTemperature decrease, ΔT = TF − TW.
fCF
S is the solubility of the compound in the
organic solvent at TF. These solubilities were measured gravimetrically.
gAbsolute supersaturation, ΔC = CI − CFS. hSupersaturation ratio S = CI/CFS.
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approximately 15 mg were weighed into 100 μL aluminum pans and
heated at 5 K min−1 from 298 to 380, 443, and 473 K for ibuprofen,
aspirin, and naproxen, respectively, under nitrogen (60 mL/min).
3. RESULTS AND DISCUSSION
3.1. Crystallization Conditions of Aspirin, Cholesterol,
Naproxen, Ibuprofen, and Acetaminophen. Table 1
summarizes the operating conditions of crystallization experi-
ments of model drugs aspirin (ASP), cholesterol (COL),
naproxen (NAP), ibuprofen (IBU), and acetaminophen
(ACPH). For each experiment is shown the final temperature
TF achieved during the depressurization, when the crystal-
lization occurs, and the solubility of each compound at TF
(CF
S), which allows the calculation of the corresponding
absolute supersaturation ΔC and the supersaturation ratio S
achieved. Aspirin and cholesterol were processed at different
values of initial concentration CI and CO2 molar fraction XW.
The effect of these parameters on the supersaturation generated
and hence on particle size is discussed in section 3.2.
Appropriate operating conditions CI and XW were chosen
according to solubility behavior of the different drugs in the
corresponding “organic solvent/CO2” mixtures, so that in the
second step of the process the CO2-expanded mixture presents
a single liquid phase; see Figure 1. For achieving successful
crystallizations, experiment conditions must ensure the
preservation of the experiments in the liquid region of the
system, along or close below the solubility curve. The solubility
curve of aspirin in CO2-expanded acetone,
14 and working
conditions of experiments ASP2 and ASP3 are represented in
Figure 2. As the Figure shows, crystallization experiments ASP2
and ASP3 are situated along the solubility curve. Solubility
curves of aspirin in CO2-expanded ethanol, and those of
cholesterol, naproxen, ibuprofen and acetaminophen in the
corresponding CO2-expanded solvents are described in
previous work.15−18
As shown in Table 1, the higher the CO2 content in the
mixture (XW), the higher the temperature decrease (ΔT)
achieved. The explanation for this is the following. In the
depressurization step, CO2 evaporates and takes the heat
required for its vaporization from the organic solution in which
it was dissolved, causing an abrupt temperature decrease.
Therefore, increasing the CO2 amount in the mixture results in
an increase of the heat required for the CO2 phase change, and
thereby a larger solution temperature decrease, ΔT, is
observed.9−11 In contrast with conventional cooling crystal-
lizations, the temperature decrease in a DELOS process is
ideally homogeneous, since the extension of the CO2
evaporation is exactly the same throughout the solution,
causing an extremely homogeneous increase of the super-
saturation over all the solution. The large supersaturation,
rapidly and homogeneously achieved, is the reason why
micrometer-sized powders with low polydispersitivity are
obtained. The table also shows for each experiment the
corresponding API solubility in the organic solvent at the
depressurization temperature (CF
S). The high solubility
variation from TW to TF generates a supersaturation of the
solution and the crystallization of the drug particles.
Experiments ASP1-ASP2 and CHOL1-CHOL2 show that for
given operating conditions, increasing XW results in an increase
of ΔT. In experiments ASP1-ASP2, an increase in XW from 0.40
to 0.47 results in an increase in ΔT from −27 K to −33 K.
Experiments COL1-COL2 show that increasing XW from 0.50
to 0.64 results in an increase from −50 K to −60 K in ΔT.
Since in these conditions the solubility decreases with a
decrease of the depressurization temperature, the absolute
supersaturation and the supersaturation ratio achieved in ASP2
(ΔC = 0.022 mol/mol; S = 1.5) and CHOL2 (ΔC = 0.0048
mol/mol; S = 17) are higher than in ASP1 (ΔC = 0.014 mol/
mol; S = 1.3) and CHOL1 (ΔC = 0.0045 mol/mol; S = 9)
respectively. In conclusion, increasing the CO2 content results
in an increase of the supersaturation attained in the
crystallization experiments. The solubility variation with
temperature depends on the compound and solvent nature.
Aspirin solubility in acetone decreases linearly with temperature
in the range from 250 to 300 K, while cholesterol solubility in
ethanol shows an exponential behavior, and no significant
solubility variation is observed below 275 K (see Figure 5).
On the other hand, experiments ASP3-ASP4 and CHOL3-
CHOL4 were performed at different initial concentrations CI,
keeping constant the rest of the operating parameters. As
experiments ASP3-ASP4 show, increasing the initial concen-
tration from 3.5 × 10−2 mol/mol to 5.2 × 10−2 mol/mol
provokes an increase of the supersaturation ratio S from 1.3 to
1.9. Regarding cholesterol crystallization experiments COL3-
COL4, increasing CI from 2.6 × 10
−3 mol/mol to 3.8 × 10−3
mol/mol also results in an increase in S from 9 to 13.
Therefore, increasing the initial concentration CI provokes an
increase of the supersaturation achieved in the crystallizations.
3.2. Crystallization Outcome. Powder Characteriza-
tion and Effect of Process Parameters on Particle Size.
In all experiments summarized in Table 1 finely divided
powders with micrometric size and homogeneous and defined
morphology were obtained. Figure 3 shows some representative
SEM images of the particles produced by the crystallization
experiments. Crystals of aspirin and cholesterol consist of finely
shaped prisms with irregular edges and very well developed
basal faces. Plate-like crystals of homogeneous morphology and
with very developed basal faces are obtained from the
crystallization of naproxen. Aspirin, cholesterol, and naproxen
crystals have an especially low aspect ratio. Ibuprofen particles
show plate-like crystals of irregular shape. Acetaminophen
processed particles show well-faceted prismatic crystals.
The particulate samples of the model drugs produced by the
process studied were highly crystalline and consisted of pure
Figure 2. Solubility curve (continuous line) fitted through
experimental solubility data (*) of aspirin (found in ref 9) in CO2-
expanded acetone, and working points of experiments ASP2 and ASP3
at PW = 7 MPa and TW = 295 K. Working lines (black dashed lines)
depict the evolution of the solute concentration by addition of pure
CO2 in experiments ASP2 and ASP3.
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polymorphic phases, as happened when processing stearic
acid.19 As can be seen in Figure 4, powder X-ray diffraction
(PXRD) patterns of processed aspirin particles and raw aspirin
particles correspond to the most usual polymorph of aspirin
described so far, the PXRD pattern of which has been simulated
from its crystalline structure.20,21 Some differences in the
relative peak intensities of raw aspirin are found probably due
to the preferred orientation of microcrystals caused by the high
particle size and plate-like morphology of the starting material.
Processed cholesterol and raw cholesterol show the same
PXRD pattern and correspond to the anhydrous and most
stable polymorph of cholesterol at room temperature.22 The
PXRD pattern of this polymorph has been simulated from the
single crystal structure. The same results concerning poly-
morphism were observed when comparing naproxen, acet-
aminophen, and ibuprofen processed by the method studied
with their corresponding starting materials (also shown in
Figure 4), after processing the crystal form is the same as that of
the starting material. This form corresponds to the most stable
polymorph of acetaminophen,23 and the other to the only
reported crystalline structures of naproxen24 and ibuprofen.25
Starting materials lead to PXRD patterns with some variations
on peak relative intensities in relation to those obtained from
the processed particles patterns probably due to preferred
orientation. By TG analysis we have observed that the amount
of residual solvent in all processed samples is below the
standard ICH acceptable limits for class 3 solvents (5000
ppm).5 TG analyses do not show mass lost during heating from
room temperature to 373.15 K, so there is no need for further
drying steps.
3.2.1. Effect of Operational Parameters on Drug Particle
Size. Table 2 shows the crystallization yields and particle size
distributions obtained, as well as the real supersaturation ratio S
achieved in each crystallization experiment, which has been
calculated from the initial concentration CI and the drug
solubility at the depressurization temperature CF
S (shown in
Table 1).
Different particle size distributions were obtained depending
on the operating conditions. Crystallization of aspirin from
CO2-expanded acetone gave powder samples with a medium
particle diameter between 14 and 31 μm, depending on the
operating conditions. By processing cholesterol from the same
solvent mixture, particle sizes between 0.5 and 2 μm were
straightforwardly achieved. Volumetric particle size distribu-
tions show an important fraction (10%) of cholesterol particles
included in the sub-micrometer range. The low uniformity
index indicates a narrow particle size distribution. Naproxen
processed particles have a medium particle size of 10 μm.
Ibuprofen particles present a medium particle size of 8 μm,
while acetaminophen particles have a medium diameter of 19
μm.
Crystallization experiments of aspirin (ASP) and cholesterol
(COL), shown in Table 1, were carried out at different values
of initial solute concentration (CI) and CO2 molar fraction
(XW) to gain a better insight into the effects of these
operational parameters on the characteristics of the processed
drugs, in terms of particle size.
Experiments ASP1-ASP2 and COL1-COL2 were performed
over initial solutions of aspirin and cholesterol, respectively,
varying the CO2 content, XW, while keeping constant the rest of
process parameters. As shown in Table 2, under these
conditions, aspirin medium particle size decreases from 31.4
to 23.4 μm when XW is increased from 0.40 to 0.47, and
cholesterol medium particle size decreases from 1.2 to 0.5 μm
Figure 3. SEM images of DELOS processed drugs. Top images, from left to right: aspirin, experiment ASP3; cholesterol, experiment COL2,
naproxen, experiment NAP1. Bottom images, from left to right: ibuprofen, experiment IBU1 and acetaminophen, experiment ACPH1.
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when the CO2 content is increased from 0.50 to 0.64. As
discussed in section 3.1, this result can be explained by the
larger temperature reduction achieved during the depressuriza-
tion step (ΔT): augmenting this temperature reduction ΔT
provokes a decrease in CS
F, and a more pronounced increase of
the supersaturation attained during the depressurization of the
Figure 4. X-ray powder diffraction spectra of (a) aspirin; (b) cholesterol; (c) naproxen; (d) acetaminophen; and (e) ibuprofen. For each product the
lower trace corresponds to the pattern of the starting material, the middle one to the processed particles, and the upper to the simulated
diffractograms of the most common polymorph reported for aspirin, the most stable polymorph of cholesterol at room temperature, acetaminophen
polymorph I and the unique reported ibuprofen crystalline structure.
Table 2. Supersaturation and Crystallization Outcome: Yield and Particle Size Distribution
particle sizeh (μm)
expa solvent CI
b(mol/mol) XW
c ΔTd (K) ΔCe (mol/mol) Sf yieldg (%) d(0.1) d(0.5) d(0.9) UIi)
ASP1 acetone 7.0 × 10−2 0.40 −27 0.014 1.3 20 10.5 31.1 73.7 14
ASP2 acetone 7.0 × 10−2 0.47 −33 0.022 1.5 30 8.1 23.4 59.2 14
ASP3 acetone 5.2 × 10−2 0.55 −48 0.024 1.9 40 5.9 16.5 42.6 14
ASP4 acetone 3.5 × 10−2 0.55 −48 0.007 1.3 10 4.3 30.5 58.0 7
ASP5 ethanol 8.1 × 10−2 0.55 −64 0.076 17 80 3.9 13.7 27.3 14
COL1 acetone 5.1 × 10−3 0.50 −50 0.0045 9 80 0.3 1.2 9.3 3
COL2 acetone 5.1 × 10−3 0.64 −60 0.0048 17 85 0.2 0.5 4.5 4
COL3 acetone 3.8 × 10−3 0.71 −70 0.0035 13 85 0.3 1.2 6.0 5
COL4 acetone 2.6 × 10−3 0.71 −75 0.0023 9 75 0.5 2.1 10.0 5
NAP1 ethanol 8.8 × 10−3 0.80 −90 0.007 4 50 6.0 10.0 35.0 17
IBU1 acetone 1.7 × 10−1 0.80 −75 0.152 9 60 3.5 8.0 17.0 21
ACPH1 ethanol 6.6 × 10−2 0.40 −40 0.032 2 10 3.5 18.6 34.5 10
aASP means aspirin; COL means cholesterol; NAP means naproxen; IBU means ibuprofen; ACPH means acetaminophen. bCI is the concentration
of solute in the initial organic solution, cCO2 content, XW = CO2 molar fraction in the solvent mixture.
dTemperature decrease, ΔT = TF − TW.
eAbsolute supersaturation, ΔC = CI − CFS. fSupersaturation ratio S = CI/CFS. gCrystallization yield = 100·(recovered mass of solids/initial mass of
solids). hVolumetric particle size distributions are described by d(0.1), d(0.5), and d(0.9), which are the particles diameters (μm) under which there
are 10%, 50%, and 90% of the total volume of the particles, respectively. d(0.5) is the volume median particle diameter. i)Uniformity index is defined
as UI = d(0.1)/d(0.9) × 100.
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CO2-expanded solution (Step 3 in Figure 1), that favors
nucleation over crystal growth, therefore obtaining smaller
particle sizes.
To test the effect of the initial solute concentration (CI),
experiments ASP3-ASP4 and COL3-COL4 were performed
varying CI while keeping constant the rest of the operating
parameters. As expected, for each solute, at constant PW, TW,
and CO2 content, particle size decreases with increasing CI. In
aspirin experiments ASP3-ASP4, increasing CI from 3.5 × 10
−2
mol/mol to 5.2 × 10−2 mol/mol results in a medium particle
size reduction from 30.5 to 16.5 μm, due to an increase of the
supersaturation ratio S from 1.3 to 1.9. Cholesterol
crystallizations COL3-COL4 showed a particle reduction
from 2.1 to 1.2 μm when CI was increased from 2.6 × 10
−3
mol/mol to 3.8 × 10−3 mol/mol, which caused S to rise from 9
to 13.
In summary, the higher the XW and CI values, the higher the
supersaturation attained in the experiment, which contributes
to a decrease the size of the crystals produced. Nevertheless, XW
and CI cannot be increased without limit, since the drug
solubility behavior in the CO2- expanded solvent limits the
operating conditions (see Figure 2).
Experiments ASP2-ASP3 (Figure 2) and COL2-COL3,
performed along the solubility curve, were used to compare
the weight of CI and XW parameters on the supersaturation
achieved and on particle characteristics, and discern which
parameter yields a more important decrease in particle size.
Results in Table 2 show that experiment ASP3, performed at
lower CI and higher XW (CI = 5.2 × 10
−2 mol/mol, XW = 0.55)
than ASP2 (CI = 7.0 × 10
−2 mol/mol, XW = 0.47), presents a
larger particle size reduction (d(0.5)ASP3 = 16.5 μm, d(0.5)ASP2
= 23.4 μm). In contrast, COL2 experiment, performed at
higher CI and lower XW (CI = 5.1 × 10
−3 mol/mol, XW = 0.64)
than COL3 (CI = 3.8 × 10
−3 mol/mol, XW = 0.71), yields the
smallest particles (d(0.5)COL2 = 0.5 μm, d(0.5)COL3 = 1.2 μm).
The reason for the observed different weights of CI and XW on
particle characteristics of aspirin and cholesterol experiments
can be rationalized as follows, taking into account the
supersaturation evolution which occurred during the three
steps of the process studied, represented in Figure 1.
Absolute supersaturation values ΔC for experiments ASP2-
ASP3 and COL2-COL3, also shown in Table 2, have been
represented in Figure 5, using the solubility evolution of aspirin
and cholesterol with temperature, also represented in the same
figure as curves fitted to experimental solubility measurements.
As Figure 5 shows, in the temperature range studied aspirin
solubility in acetone decreases linearly with decreasing
temperature. Therefore, in aspirin crystallizations, achieving a
lower depressurization temperature results in a remarkably
lower solubility at TF. When comparing supersaturation values
of experiments ASP2-ASP3, it can be observed that ΔCASP3
(0.024 mol/mol) is slightly higher than ΔCASP2 (0.022 mol/
mol), since the difference between solubility at the final
temperature, CF
S, of ASP3 and ASP2 is higher than the
difference between the initial concentrations CI of both
experiments. This observation explains the higher particle size
reduction obtained in ASP3. In contrast, Figure 5 shows that
for cholesterol experiments, ΔCCOL2 (0.0048 mol/mol) is
remarkably higher than ΔCCOL3 (0.0035 mol/mol). The
solubility variation of cholesterol in acetone shows an
exponential behavior, with no significant variation of solubility
at temperatures below 275 K. As discussed before, increasing
the CO2 content XW results in a decrease in the
depressurization temperature TF. In this case, increasing the
CO2 content of the mixture to reach a lower TF will not result
in a significant increase of the supersaturation attained, and the
variation of the initial concentration CI will produce a more
pronounced effect on the supersaturation achieved in the
crystallization. In experiments COL2-COL3, the difference in
supersaturation is governed by the difference in the initial
concentration.
Therefore, in ASP3 and COL2 it has been possible to reach
higher supersaturation values, and consequently higher
nucleation rates, than in ASP2 and COL3, respectively,
allowing the formation of smaller particle sizes. Summarizing,
in aspirin experiments performed over the solubility curve, an
increase in XW is more dominant producing higher super-
saturations than an increase in CI. Conversely, in cholesterol
experiments higher CI values are revealed as more important
than higher XW values, since cholesterol solubility (CF
S) does
not change significantly from 275 K to lower temperatures,
whereas the solubility of aspirin changes linearly with
temperature. Therefore, it is possible to predict the relative
weight of process parameters CI and XW on particle
characteristics by simply determining the solubility variation
with temperature of the compound to be crystallized in the
corresponding organic solvent at atmospheric pressure.
It should also be pointed out that yields obtained in
cholesterol crystallizations are remarkably higher than those
obtained in aspirin crystallizations from acetone/CO2. Experi-
ment COL2 produced a yield of 85% in mass of particles
produced, whereas ASP3 produced a 40% yield. The reason for
the difference in effectiveness of the crystallization process
studied is again a consequence of the different solubility rise
with temperature seen in Figure 5. In cholesterol experiments,
Figure 5. Solubility versus temperature evolution of (top) aspirin and
(bottom) cholesterol in acetone solutions. Experimental measure-
ments (■) obtained through a static gravimetric method were fitted to
linear and exponential functions for aspirin and cholesterol,
respectively. Degrees of absolute supersaturation ΔC = CI − CFS
obtained in each experiment are also represented.
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solubility at TF is an order of magnitude lower than solubility at
TW (10
−4 mol/mol vs 10−3 mol/mol). This fact allows the
production of a very powerful supersaturation increase during
the depressurization step provoking the crystallization of most
of the compound dissolved before this step. On the other hand,
in aspirin experiments from expanded acetone, when temper-
ature decreases from TW to TF, the solubility of the compound
is only lowered to a half. Hence, the supersaturation generated
is less important than in the case of cholesterol and
consequently an important mass of aspirin remains in solution
despite the temperature decrease. However, as Table 2 shows,
experiment ASP5 performed using expanded ethanol gave an
80% yield of powdered aspirin, compared with 40% obtained in
ASP4 from expanded acetone. Crystallization yield of processed
aspirin can be remarkably improved by using CO2 expanded
ethanol as the medium, since solubility variation with
temperature of aspirin in ethanol is higher than that in acetone.
4. INDUSTRIAL VIABILITY OF THE DELOS PROCESS
The process studied was successfully scaled-up by 7-fold from
laboratory (300 mL vessel volume) to pilot plant scale (2000
mL) by performing precipitation experiments using aspirin as a
model drug. Experiments at each scale were repeated twice with
reproducible results. The results, summarized in Table 3, show
an extremely high reproducibility, both in terms of particle size
and precipitation yield. The scale-up design was simply done by
geometric factors, since the technical complexity of the required
equipment is very low. Compared with conventional
crystallizations from liquid solvents, the inherent features of
the crystallization process studied make it very easy to scale-up,
avoiding classical scaling-up troubles such as those related to
agitation. In conventional cooling crystallizations, the stirring
rate and the stirrer design determine the supersaturation
homogeneity and therefore the homogeneity in particle size.
When scaling up, this parameter becomes critical: the bigger the
crystallization vessel, the bigger the gradient temperature from
the vessel walls to the center, giving very heterogeneous
supersaturation profiles and poor reproducibility which
complicate scale-up thereof. Since in the process studied the
stirring is only used in the pressurization step, to achieve a
faster mixing of the CO2 with the organic solvent, and it is not
needed in the depressurization step, where the crystallization
occurs, the homogeneity of the supersaturation achieved is
independent of the vessel volume and the stirring rate is not
affecting the final characteristics of the precipitated particles.
Another remarkable point which eases a scale-up design of the
reported crystallization method is the fact that the depressu-
rization takes place by just opening a simple valve.
Even so, the industrial application of this process will only be
possible if, at the present process development stage, it can be
shown to be industrially viable from the technical, economical,
and environmental points of view. For this purpose, in a recent
study, we have evaluated the feasibility of this crystallization
method for the industrial production of micrometer or
submicrometer-sized particulate drugs.13 On the basis of
experimental data, we first designed a cGMP (Good
Table 3. Scale-Up Experiments Performed from “Acetone/CO2” Mixtures with Aspirin As a Model Drug
diameter of particlesa (μm)
exp vessel vol (mL) expanded mixture PW (MPa) TW (K) CI (mol/mol) XW yield (%) ΔT (K) d(0.1) d(0.5) d(0.9)
ASP3 300 acetone/CO2 7 295 5.2 × 10
−2 0.55 40 −48 5.9 16.5 42.6
ASP6 2000 acetone/CO2 7 295 5.2 × 10
−2 0.55 40 −45 4.7 15.0 41.0
aVolumetric particle size distributions are described by d(0.1), d(0.5), and d(0.9), which are the particles diameters (μm) under which there are 10%,
50%, and 90% of the total volume of the particles, respectively. d(0.5) is the volume median particle diameter.
Figure 6. Calculated sustainability indexes of a theoretical industrial GMP multiproduct plant for producing 50 tonnes per year of micrometer-sized
API, versus real indexes of a real conventional crystallization pharmaceutical plant of the same capacity.13 (a) Materials Index: kg of consumed raw
materials per kg of final product. (b) Energy index: kg of consumed natural gas (kg of gas equivalents to kJ of gas, oil, electricity, and steam) per kg of
final product. (c) Water index: kg of consumed water (process and utility water) per kg of final product. This plant design does not consume water.
(d) Contamination index: kg of greenhouse gases emitted per kg of final product.
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Manufacturing Practices) multiproduct plant for producing 50
tonnes of micrometer-sized APIs per year. The design turned
out to be perfectly viable according to GMP’s rules, since the
following characteristics, among others, are easily achieved:
process parameters are easily registered; closed equipment is
used, avoiding exposure of the workers to the products and
exposure of the products to the atmosphere, and the entire
process is performed in a single area, avoiding transport and
loss of material from unit to unit and decreasing product
contamination risks. Compared with conventional multistep
procedures, decreasing process units also simplifies the related
quality documentation. The high reproducibility and batch-to-
batch consistency of the process studied also allow the
recirculation of the mother liquor in the subsequent
crystallization cycle, which has been limited to a given number
of recirculations. Finally, the cleaning of the equipment after
each batch can be done by using CO2-expanded solvents at
high pressure, and its efficiency evaluated by analyzing samples
of the cleaning solvent.
From the technical point of view, the equipment needed for
building an industrial plant is already available. During recent
years, industrial supercritical CO2 extraction facilities, which use
similar pressure vessels and related equipment, and which work
at higher working pressures and use bigger vessel volumes than
the ones required for a plant working under the methodology
described, have been produced around the world.26 Hence,
technically, an industrial scale-up is perfectly viable.
The evaluation of the environmental sustainability of this
process, compared with conventional crystallizations from
liquid solvents, also showed very interesting results. Figure 6
represents the sustainability indexes of the designed plant
versus a real conventional crystallization pharmaceutical plant
of the same capacity. Sustainability indexes are quantitative
indicators that account for the necessary amount of materials,
energy, water needed, and contamination emitted for producing
1 kg of product.27 The materials index represents the kilogram
of consumed raw materials per kilogram of final product, the
energy index accounts for the kilogram of consumed natural gas
(kilogram of gas equivalents to kJ of gas, oil, electricity, and
steam) per kilogram of final product, the water index represents
the kilogram of water consumed (process and utility water) per
kilogram of final product, and the contamination index shows
the kilogram of greenhouse gases emitted per kilogram of final
product. Sustainability indexes have been calculated from mass
and energy balances. In all cases, the indexes of the designed
plant were significantly lower than the corresponding to the
conventional crystallization plant, meaning that the studied
crystallization process is a greener and environmentally more
friendly process than conventional pharmaceutical crystalliza-
tion procedures.
Preliminary economic aspects were also estimated. The total
capital investment required for the CF-based plant, estimated
from equipment costs, according to the multiplying factors
method reported by Peter, Timmerhaus and West,28 turns out
to be much lower (∼10 times lower) than the investment
required for a real pharmaceutical crystallization plant of the
same capacity.13 Thus, the comparison of environmental and
economic aspects of the designed plant with real conventional
multistep crystallization processes, reveals important and
attractive advantages of the CO2-based process.
5. CONCLUSIONS
The DELOS process, based on the use of compressed fluids, is
an efficient crystallization method for the one -step production
of crystalline micrometer-sized particles of active pharmaceut-
ical ingredients, such as aspirin, cholesterol, naproxen,
ibuprofen, and acetaminophen, with high polymorphic purities
and no detectable residual solvent content by TGA. In addition,
the actual particle size of the processed powders can be
modulated by controlling operational parameters, such as the
CO2 content of the expanded solution, and the concentration
of the initial solution. The influence of these process
parameters on nucleation rates and on products characteristics
can be predicted from solubility data through the methodology
presented here for the first time. This new process can provide
real advantages over conventional crystallization processes, such
as (1) high purity products, (2) control of crystal poly-
morphism, (3) in-process elimination of residual solvent/
reduction of residual solvent levels, (4) processing of
thermolabile and waxy compounds, (5) single-step in single-
area process, (6) easy and reproducible scale-up, (7) environ-
mentally friendly technology, (8) technically and economically
viable process at industrial scale.
However, the slow implementation rates of compressed
fluids-based methodologies at industrial level could be
attributed to the strict and inflexible requirements that
pharmaceutical companies have to satisfy for changing their
production procedures.
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: ventosa@icmab.es (N.V.), vecianaj@icmab.es (J.V.).
■ ACKNOWLEDGMENTS
This work was supported by grants from DGI, Spain, projects
CONSOLIDER-C EMOCIONA (CTQ2006- 06333/BQU),
POMAS (CTQ2010- 019501), and NANOFAR (NAN2004-
09159-C04-01) and to DGR, Catalunya (project 2005SGR
00591). We acknowledge financial support from Instituto de
Salud Carlos III, through “Acciones CIBER”. The Networking
Research Center on Bioengineering, Biomaterials and Nano-
medicine (CIBER-BBN) is an initiative funded by the VI
National R Plan 2008-2011, Iniciativa Ingenio 2010, Consolider
Program, CIBER Actions and financed by the Instituto de
Salud Carlos III with assistance from the European Regional
Development Fund. E. Moreno acknowledges the MICINN for
a Juan de la Cierva postdoctoral contract. E. Rojas thanks the
CSIC for her PhD bursary. Nora Ventosa thanks Banco de
Santander for the chair of Knowledge and Technology Transfer
Parc de Recerca UABSantander. We also thank TECNIO
network for financial support on technological transfer activities
related to this work. We also thank R. Solanas (ICMAB) for the
operation of high-pressure facilities at the ICMAB, Dr. Ricard
Alvarez and Dr. Jaume Comas for their assistance during the
performance of particle size measurements, as well as the UAB
Microscopy service for their help in recording SEM images. We
would like to thank Prof. Gurnos Jones for the English revision
and correction of the manuscript.
■ REFERENCES
(1) (a) Jinno, J.; Kamada, N.; Miyake, M.; Yamada, K.; Mukai, T.;
Odomi, M.; Toguchi, H.; Liversidge, G.; Higaki, K.; Kimura, T. J.
Crystal Growth & Design Article
dx.doi.org/10.1021/cg200356x | Cryst. Growth Des. 2012, 12, 1717−17261725
Controlled Release 2006, 111, 54−64. (b) Yu Shekunov, B.; York, P. J.
Cryst. Growth 2000, 211, 122.
(2) Otsuka, M.; Kaneniwa, N. Int. J. Pharm. 1990, 62 (1), 65.
(3) Banakar., U. V., Ed. Pharmaceutical Dissolution Testing. In Drugs
and the Pharmacutical Sciences Series; Marcel Dekker: New York, 1992;
Vol. 49.
(4) (a) Findlay, G. F. Kermani; Novel Drug Delivery Technologies and
Drug Development Business Briefing - PharmaTech 2001, 166.
(b) Samler, C. Eur. Pharm. Rev. 1998, 4, 61−63. (c) Bennet, J.;
Nichols, F.; et al. J. Oral Maxillofacial Surg. 1998, 56 (11), 1249−1254.
(d) Obeye, J.; Mannaerts, B.; et al. Hum. Reprod. 2000, 15 (2), 245−
249.
(5) International Conference for Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use.
ICH. Harmonised Tripartite Guideline Impurities: Guideline for
Residual Solvents Q3C(R4). Current Step 4 version dated February
2009. Parent Guideline dated 17 July 1997.
(6) (a) Jung, J.; Perrut, M. J. Supercrit. Fluids 2001, 20, 179. (b) Wei,
M.; Musie, G. T.; Busch, D. H.; Subramaniam, B. J. Am. Chem. Soc.
2002, 124, 2513.
(7) Palakodaty, S.; York., P. Pharm. Res. 1999, 16, 976.
(8) Foster, N.; Mammucari, R.; Dehghani, F.; Barret, A.; Bezanehtak,
K.; Coen, E.; Combes, G.; Meure, L.; Regtop, A.; Tandya, A. Ind. Eng.
Chem. Res. 2003, 42, 6479.
(9) Ventosa, N.; Sala, S.; Torres, J.; Llibre, J.; Veciana, J. Cryst.
Growth Des. 2001, 1, 299.
(10) Ventosa, N.; Veciana, J.; Rovira, C.; Sala, S. (Carburos Metal̀icos
S.E.). Method for Precipitating Finely Divided Solid Particles PCT/
ES01/00327, August 2000.
(11) Ventosa, N.; Sala, S.; Veciana, J. J. Supercrit. Fluids 2003, 26, 33.
(12) Mullin, J. W. Crystallization; Butterworth Heinemann, Oxford,
2000; p 189.
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Thesis, Chemical Engineering Department, Universitat Politec̀nica de
Catalunya. 2009.
(14) Wubbolts, F. E. Ph.D. Thesis: Supercritical crystallization.
Volatile components as (anti-) solvents. Universal Press Science
Publishers: The Netherlands, 2000; p 50.
(15) Gimeno, M.; Ventosa, N.; Veciana, J.; Boumghar, Y.; Fournier,
J.; Boucher, I. Cryst. Growth Des. 2006, 6, 23−25.
(16) Cano-Sarabia, M.; Ventosa, N.; Sala, S.; Patiño, C.; Arranz, R.;
Veciana, J. Langmuir 2008, 24, 2433−2436.
(17) Munto,́ M.; Ventosa, N.; Sala, S.; Veciana, J. J. Supercrit. Fluids
2008, 47, 147−153.
(18) Sala, S.; Tassaing, T.; Ventosa, N.; Danten, Y.; Besnard, M.;
Veciana, J. ChemPhysChem 2004, 5, 243.
(19) Sala, S.; Elizondo, E.; Moreno, E.; Calvet, T.; Cuevas-Diarte, M.
A.; Ventosa, N.; Veciana, J. Cryst. Growth Des. 2010, 10, 1226−1232.
(20) Wheatley, P. J. J. Chem Soc. 1964, 6036.
(21) Vishweshwar, P.; McMahon, J. A.; Oliveira, M.; Peterson, M. L.;
Zawarotko, M. J. J. Am. Chem. Soc. 2005, 127, 16802.
(22) Shieh, H. S.; Hoard, L. G.; Nordman, C. E. Acta Crystallogr.
1981, B37, 1538.
(23) Haisa, M.; Kashino, S.; Kawai, R.; Maeda, H. Acta Crystallogr.
1976, B32, 1283.
(24) Kim, Y. B.; Song, J.; Park., I. Y. Arch. Pharm. Res. 1987, 10, 232.
(25) McConnell, J. F. Cryst. Struct. Commun. 1974, 3, 73.
(26) Perrut, M. Ind. Eng. Chem. Res. 2000, 39, 4531−4535.
(27) Bonanza, N. Estudi de sostenibilitat comparatiu dels processos
batch vs continu en la hidrogenacio ́ d’olis. Master Thesis, Chemical
Engineering Department, Universitat Politec̀nica de Catalunya, 2005.
(28) West, M. S.; Timmerhaus, K.; West, R. E., Eds.; Plant Design and
Economics for Chemical Engineers, 5th ed.; McGraw-Hill: New York,
2003.
Crystal Growth & Design Article
dx.doi.org/10.1021/cg200356x | Cryst. Growth Des. 2012, 12, 1717−17261726
